D-dimer tests demand in China grows amidst COVID-19: GlobalData
The demand, due to the monitoring of COVID-19, is seen to drive the market at a 10% CAGR between 2020 and 2025.
The D-dimer tests market in China is seeing a growing demand due to the monitoring of D-dimer levels in COVID-19 cases, setting to lead the market at a compound annual growth rate of about 10% between 2020 and 2025, according to GlobalData.
Physicians in China are preferring D-dimer tests, often used as a “biomarker” for the diagnosis conditions such as pulmonary embolism, deep vein thrombosis and disseminated intravascular coagulation,” potential prognostic marker to assess the disease severity of the COVID-19 patients,” Gundreddy Gopinadh, Medical Devices Analyst at GlobalData, said.
“In China, COVID-19 cases have grown significantly in the past few weeks and there is a growing concern this disease may spread fast and to a much wider geographic region compared to the first time it was reported in 2019,” Gopinadh said.
He also said that the D-dimer point of care (POC) test market in China accounted for 40% of the D-dimer market in 2020. “Growing number of severe COVID-19 infected patients and the necessity for quick coagulopathy testing is expected to further boost the D-dimer POC tests market in the country.”
GlobalData said that D-dimer tests are useful in monitoring and predicting the progression of a COVID-19-related risk of a patient such as thromboembolism and cytokine storm. It is also helpful in deciding when a COVID-19 patient would require hospital admission in the first week of infection and “help in timely medical interventions.”
GlobalData also said that its Hemostasis Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 market impact) report showed that Siemens Healthineers AG, Quidel Corp and Werfen Life Group SAU were the leading players in China in 2020